Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CureVac N.V (CVAC) Assets: 2019-2025

Historic Assets for CureVac N.V (CVAC) over the last 4 years, with Jun 2025 value amounting to $779.8 million.

  • CureVac N.V's Assets rose 30.04% to $779.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $779.8 million, marking a year-over-year increase of 30.04%. This contributed to the annual value of $857.9 million for FY2024, which is 1.15% up from last year.
  • According to the latest figures from Q2 2025, CureVac N.V's Assets is $779.8 million, which was down 0.13% from $780.8 million recorded in Q1 2025.
  • In the past 5 years, CureVac N.V's Assets ranged from a high of $2.2 billion in Q2 2021 and a low of $599.6 million during Q2 2024.
  • Moreover, its 3-year median value for Assets was $853.0 million (2023), whereas its average is $849.6 million.
  • Its Assets has fluctuated over the past 5 years, first crashed by 54.45% in 2022, then spiked by 30.04% in 2025.
  • Over the past 5 years, CureVac N.V's Assets (Quarterly) stood at $1.3 billion in 2021, then crashed by 33.74% to $877.9 million in 2022, then decreased by 3.39% to $848.1 million in 2023, then climbed by 1.15% to $857.9 million in 2024, then spiked by 30.04% to $779.8 million in 2025.
  • Its Assets stands at $779.8 million for Q2 2025, versus $780.8 million for Q1 2025 and $857.9 million for Q4 2024.